Literature DB >> 26341511

Does the Implantation Technique for Totally Implantable Venous Access Ports (TIVAPs) Influence Long-Term Outcome?

Daniele Biacchi1, Paolo Sammartino2, Simone Sibio2, Fabio Accarpio2, Maurizio Cardi2, Paolo Sapienza2, Alessandro De Cesare2, Joseph Maher Fouad Atta2, Alessio Impagnatiello2, Angelo Di Giorgio2.   

Abstract

BACKGROUND: Totally implantable venous access ports (TIVAP) are eventually explanted for various reasons, related or unrelated to the implantation technique used. Having more information on long-term explantation would help improve placement techniques.
METHODS: From a series of 1572 cancer patients who had TIVAPs implanted in our center with the cutdown technique or Seldinger technique, we studied the 542 patients who returned to us to have their TIVAP explanted after 70 days or more. As outcome measures we distinguished between TIVAPs explanted for long-term complications (infection, catheter-, reservoir-, and patient-related complications) and TIVAPs no longer needed. Univariate and multivariate analyses were run to investigate the reasons for explantation and their possible correlation with implantation techniques.
RESULTS: The most common reason for explantation was infection (47.6 %), followed by catheter-related (20.8 %), patient-related (14.7 %), and reservoir-related complications (4.7 %). In the remaining 12.2 % of cases, the TIVAP was explanted complication free after the planned treatments ended. Infection correlated closely with longer TIVAP use. Univariate and multivariate analyses identified the Seldinger technique as a major risk factor for venous thrombosis and catheter dislocation.
CONCLUSIONS: The need for long-term TIVAP explantation in about one-third of cancer patients is related to the implantation techniques used.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26341511     DOI: 10.1007/s00268-015-3233-z

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  17 in total

1.  Outcome analysis in 3,160 implantations of radiologically guided placements of totally implantable central venous port systems.

Authors:  Ulf K M Teichgräber; Stephan Kausche; Sebastian N Nagel; Bernhard Gebauer
Journal:  Eur Radiol       Date:  2011-01-05       Impact factor: 5.315

Review 2.  Management of infections related to totally implantable venous-access ports: challenges and perspectives.

Authors:  David Lebeaux; Nuria Fernández-Hidalgo; Ashwini Chauhan; Samuel Lee; Jean-Marc Ghigo; Benito Almirante; Christophe Beloin
Journal:  Lancet Infect Dis       Date:  2013-12-05       Impact factor: 25.071

3.  Randomized clinical trial comparing venous cutdown with the Seldinger technique for placement of implantable venous access ports.

Authors:  A Nocito; S Wildi; K Rufibach; P-A Clavien; M Weber
Journal:  Br J Surg       Date:  2009-10       Impact factor: 6.939

4.  Catheter fracture and cardiac migration: a rare complication of totally implantable venous devices.

Authors:  I di Carlo; P Fisichella; D Russello; S Puleo; F Latteri
Journal:  J Surg Oncol       Date:  2000-03       Impact factor: 3.454

5.  Pinch-off syndrome: a complication of implantable subclavian venous access devices.

Authors:  D H Hinke; D A Zandt-Stastny; L R Goodman; E J Quebbeman; E A Krzywda; D A Andris
Journal:  Radiology       Date:  1990-11       Impact factor: 11.105

6.  Insertion of totally implantable venous access devices: an expertise-based, randomized, controlled trial (NCT00600444).

Authors:  Phillip Knebel; Ruben Lopez-Benitez; Lars Fischer; Boris A Radeleff; Ulrike Stampfl; Thomas Bruckner; Roland Hennes; Meinhard Kieser; Hans-Ulrich Kauczor; Markus W Büchler; Christoph M Seiler
Journal:  Ann Surg       Date:  2011-06       Impact factor: 12.969

7.  Totally implantable central venous access ports for long-term chemotherapy. A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days.

Authors:  R Biffi; F de Braud; F Orsi; S Pozzi; S Mauri; A Goldhirsch; F Nolè; B Andreoni
Journal:  Ann Oncol       Date:  1998-07       Impact factor: 32.976

8.  Complications related to indwelling caval catheters on a gynecologic oncology service.

Authors:  D F Silver; R E Hempling; F O Recio; M S Piver; G H Eltabbakh
Journal:  Gynecol Oncol       Date:  1998-09       Impact factor: 5.482

9.  Reasons for explantation of totally implantable access ports: a multivariate analysis of 385 consecutive patients.

Authors:  Lars Fischer; Phillip Knebel; Steffen Schröder; Thomas Bruckner; Markus K Diener; Roland Hennes; Klaus Buhl; Bruno Schmied; Christoph M Seiler
Journal:  Ann Surg Oncol       Date:  2008-01-23       Impact factor: 5.344

10.  Ultrasound-guided central venous catheterization in cancer patients improves the success rate of cannulation and reduces mechanical complications: a prospective observational study of 1,978 consecutive catheterizations.

Authors:  Luigi Cavanna; Giuseppe Civardi; Daniele Vallisa; Camilla Di Nunzio; Lorella Cappucciati; Raffaella Bertè; Maria Rosa Cordani; Antonio Lazzaro; Gabriele Cremona; Claudia Biasini; Monica Muroni; Patrizia Mordenti; Silvia Gorgni; Elena Zaffignani; Massimo Ambroggi; Livia Bidin; Maria Angela Palladino; Carmelina Rodinò; Laura Tibaldi
Journal:  World J Surg Oncol       Date:  2010-10-19       Impact factor: 2.754

View more
  3 in total

1.  Totally Implantable Venous Access Devices: Efforts Are Needed to Standardize Procedures to Avoid Complications.

Authors:  Isidoro Di Carlo; Adriana Toro; Annalisa Ardiri; Gaetano Bertino
Journal:  World J Surg       Date:  2016-07       Impact factor: 3.352

2.  Comparison of PICC and TIVAP in chemotherapy for patients with thyroid cancer.

Authors:  Fangmei Qi; Hairong Cheng; Xiying Yuan; Li Zhang
Journal:  Oncol Lett       Date:  2020-06-15       Impact factor: 2.967

Review 3.  Risk factors for complications in cancer patients with totally implantable access ports: A retrospective study and review of the literature.

Authors:  Süleyman Bademler; Muhammed Üçüncü; İlknur Yıldırım; Hasan Karanlık
Journal:  J Int Med Res       Date:  2018-11-15       Impact factor: 1.671

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.